60421-23-0

Basic information

• Product Name: Methyl 1-amino-1-cyclopentanecarboxylate hydrochloride
• Synonyms: METHYL 1-AMINOCYCLOPENTYLCARBOXYLATE HCL;methyl 1-aminocyclopentanecarboxylate, HCl;Cycloeucine methyl ester hydrochloride;Cyclopentanecarboxylic acid, 1-amino-, methyl ester, hydrochloride;Nsc161119;1-Amino-1-cyclopentanecarboxylic acid methyl ester hydrochloride;cycloeucinemethyl ester HCL;AC5C-OMe HCl
• CAS NO: 60421-23-0
• Molecular Formula: C₇H₁₃NO₂*ClH
• Molecular Weight: 179.64
• EINECS: 200-110-4
• Product Categories: Cycloalkanes
• Mol File: 60421-23-0.mol

Chemical Properties

• Melting Point: 207-208 °C (decomp)
• Boiling Point: 186.7 °C at 760 mmHg
• Flash Point: 58.7 °C
• Appearance: /
• Density: 1.081g/cm³
• Vapor Pressure: 0.653mmHg at 25°C
• Refractive Index: 1.478
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: Methyl 1-amino-1-cyclopentanecarboxylate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1-amino-1-cyclopentanecarboxylate hydrochloride(60421-23-0)
• EPA Substance Registry System: Methyl 1-amino-1-cyclopentanecarboxylate hydrochloride(60421-23-0)

Safety Data

• Hazardous Substances Data: 60421-23-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 1-amino-1-cyclopentanecarboxylate hydrochloride is used as a building block for the synthesis of various pharmaceuticals. Its increased solubility and stability in the hydrochloride salt form make it suitable for use in pharmaceutical formulations.
Used in Agrochemical Industry:
Methyl 1-amino-1-cyclopentanecarboxylate hydrochloride is used in the synthesis of agrochemicals, contributing to the development of effective and stable products for agricultural applications.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
Methyl 1-amino-1-cyclopentanecarboxylate hydrochloride is used as a chiral auxiliary in asymmetric synthesis to control the stereochemistry of reactions. This application is crucial in the production of enantiomerically pure compounds, which are essential in various industries, including pharmaceuticals and agrochemicals, where the stereochemistry of a compound can significantly impact its biological activity and efficacy.

InChI:InChI=1/C7H13NO2/c1-10-6(9)7(8)4-2-3-5-7/h2-5,8H2,1H3

Upstream product

• 67-56-1 methanol 
• 52-52-8 1-amino-1-cyclopentanecarboxylic acid 
• 120-92-3 cyclopentanone 
• 699-51-4 1,3-diazaspiro[4.4]nonane-2,4-dione 
• 75-36-5 acetyl chloride 
• 248262-96-6 methyl 1-((tert-butoxycarbonyl)amino)cyclopentanecarboxylate 
• 1001426-16-9 [1-(1-hydroxy-1-methylethyl)cyclopentyl]carbamic acid tert-butyl ester 

Downstream Products

• 139456-12-5 7-Acetyl-9-(4-chloro-phenyl)-6,8,9-triaza-spiro[4.5]dec-7-en-10-one 
• 139456-08-9 7-Acetyl-9-p-tolyl-6,8,9-triaza-spiro[4.5]dec-7-en-10-one 
• 92398-62-4 N-(benzyloxycarbonyl)-β-benzyl-L-aspartyl-α-aminocyclopentanecarboxylic acid methyl ester 
• 139456-09-0 10-Oxo-9-p-tolyl-6,8,9-triaza-spiro[4.5]dec-7-ene-7-carboxylic acid methyl ester 
• 139456-10-3 7-Acetyl-9-(4-fluoro-phenyl)-6,8,9-triaza-spiro[4.5]dec-7-en-10-one 
• 139456-11-4 9-(4-Fluoro-phenyl)-10-oxo-6,8,9-triaza-spiro[4.5]dec-7-ene-7-carboxylic acid methyl ester 
• 139456-13-6 4-(7-Acetyl-10-oxo-6,8,9-triaza-spiro[4.5]dec-7-en-9-yl)-benzoic acid methyl ester 
• 139456-07-8 7-Acetyl-9-phenyl-6,8,9-triaza-spiro[4.5]dec-7-en-10-one 
• 94999-60-7 1-(1-Benzyloxycarbonylamino-cyclopentylcarbonylamino)-cyclopentan-carbonsaeure-⁽¹⁾-methylester 
• 840506-49-2 phenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate 
• 138401-24-8 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-[1,1'-biphenyl]-2-carbonitrile 
• 569654-43-9 1-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-cyclopentanecarboxylic acid methyl ester 
• 1263291-80-0 methyl 1-{[2-(3,5-difluorophenyl)-2-oxoethyl]amino}cyclopentanecarboxylate trifluoroacetate 

Relevant articles and documents

Hydrogen-Borrowing Alkylation of 1,2-Amino Alcohols in the Synthesis of Enantioenriched γ-Aminobutyric Acids

For the first time we have been able to employ enantiopure 1,2-amino alcohols derived from abundant amino acids in C?C bond-forming hydrogen-borrowing alkylation reactions. These reactions are facilitated by the use of the aryl ketone Ph*COMe. Racemisation of the amine stereocentre during alkylation can be prevented by the use of sub-stoichiometric base and protection of the nitrogen with a sterically hindered triphenylmethane (trityl) or benzyl group. The Ph* and trityl groups are readily cleaved in one pot to give γ-aminobutyric acid (GABA) products as their HCl salts without further purification. Both steps may be performed in sequence without isolation of the hydrogen-borrowing intermediate, removing the need for column chromatography.

Distal Stereocontrol Using Guanidinylated Peptides as Multifunctional Ligands: Desymmetrization of Diarylmethanes via Ullman Cross-Coupling

We report the development of a new class of guanidine-containing peptides as multifunctional ligands for transition-metal catalysis and its application in the remote desymmetrization of diarylmethanes via copper-catalyzed Ullman cross-coupling. Through design of these peptides, high levels of enantioinduction and good isolated yields were achieved in the long-range asymmetric cross-coupling (up to 93:7 er and 76% yield) between aryl bromides and malonates. Our mechanistic studies suggest that distal stereocontrol is achieved through a Cs-bridged interaction between the Lewis-basic C-terminal carboxylate of the peptides with the distal arene of the substrate.

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same for inhibiting human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1). The disclosed compound and the pharmaceutical composition including the same for inhibiting human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1) are excellent in activity and solubility, and is more efficient in formulation and transfer.

A COMPOUND FOR INHIBITING 11BETA-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same for inhibiting human 11-beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1). The disclosed compound and the pharmaceutical composition including the same for inhibiting human 11-beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) are excellent in activity and solubility, and is more efficient in formulation and transfer.

OxymaPure/DIC: An efficient reagent for the synthesis of a novel series of 4-[2-(2-acetylaminophenyl)-2-oxo-acetylamino] benzoyl amino acid ester derivatives

OxymaPure (ethyl 2-cyano-2-(hydroxyimino)acetate) was tested as an additive for use in the carbodiimide (DIC) approach for the synthesis of a novel series of α-ketoamide derivatives (4-[2-(2-acetylaminophenyl)-2-oxo-acetylamino] benzoyl amino acid ester derivatives). OxymaPure showed clear superiority to HOBt/DIC or carbodiimide alone in terms of purity and yield. The title compounds were synthesized via the ring opening of N-acylisatin. First, N-acetylisatin was reacted with 4-aminobenzoic acid under conventional heating as well as microwave irradiation to afford 4-(2-(2-acetamidophenyl)-2-oxoacetamido)benzoic acid. This α-ketoamide was coupled to different amino acid esters using OxymaPure/DIC as a coupling reagent to afford 4-[2-(2-acetylaminophenyl)-2- oxoacetylamino] benzoyl amino acid ester derivatives in excellent yield and purity. The synthesized compounds were characterized using FT-IR, NMR, and elemental analysis.

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y1, as modulators of the serotonin receptor of subtype 5-HT2B, as blockers of the voltage-gated potassium channel Kv1.3 and as inhibitors of the β-catenin-dependent “canonical” Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases.

SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES

The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

MONOCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of the formula (I) : (wherein variables A1, A2, A3, A4, A5, A6, A7, A8, G1, G2, G3, G4, J, Q, Ea, Eb, Ec, R6, R7, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

A PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND

The present invention provides a pyrazolo[1,5-a]pyrimidine compound, having CB1 receptor-antagonizing activity, of the following formula [I]: in which R1 and R2 are the same or different and each an optionally substituted aryl group etc, R0 is hydrogen atom, an alkyl group etc, E is a group of the formula: -C(=O)- or -SO?2#191-, R is a group of the following formula [i], [ii] or [iii] etc: Ring A is (a) a C?3-8#191 cycloalkyl group optionally fused to a benzene ring or (b) a benzene ring, Q is a single bond or a methylene group, Ring B is a 4- to 7-membered aliphatic heterocyclic group, said cyclic group binding via its ring-carbon atom to the adjacent nitrogen atom, X is sulfur atom etc, R3 is an alkyl group optionally substituted by an alkylthio group, R4 is hydrogen atom, an alkyl group etc, one of RA and RB is an alkyl group etc, and the other is hydrogen atom, an alkyl group etc, or a pharmaceutically acceptable salt thereof.